Eton Pharmaceuticals, Inc. (ETON) News
Filter ETON News Items
ETON News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ETON News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ETON News From Around the Web
Below are the latest news stories about ETON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ETON as an investment opportunity.
Investing in Eton Pharmaceuticals (NASDAQ:ETON) three years ago would have delivered you a 177% gainThe worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put... |
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®Adds an additional commercial and strategic rare disease product to Eton’s portfolioGalzin is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired Galzin® (zinc acetate). “This acquisition furthers our |
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)Acquisition bolsters Eton’s commercial pediatric endocrinology portfolioProduct is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions DEER PARK, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has completed its previously announced asset purch |
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical TrialClinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE®DEER PARK, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases announced the full readout and compelling results from the clinical trial eval |
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) top owners are retail investors with 58% stake, while 26% is held by institutionsKey Insights Eton Pharmaceuticals' significant retail investors ownership suggests that the key decisions are... |
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial OfficerMs. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rar |
Eton acquires US rights to neonatal diabetes treatment from AMMTeKAmglidia was approved by the European Medicines Agency in 2018. |
Eton Pharmaceuticals acquires U.S. rights to Amglidia from AMMTeKEton Pharmaceuticals (ETON) announced that it has acquired the U.S. rights to Amglidia for the treatment of neonatal diabetes mellitus from AMMTeK. AMMTeK has conducted a post-approval study tracking five years of real-world safety and efficacy in European patients, which will be used to support Eton’s NDA submission. Eton plans to hold a meeting with the FDA in the first quarter of 2025 and anticipates submitting an NDA for the product in 2026. Published first on TheFly – the ultimate source fo |
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in EuropeStrong strategic fit with Eton’s existing pediatric endocrinology focusAmglidia has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA)Potential New Drug Application (NDA) submission in 2026 DEER PARK, Ill., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on deve |
Eton Pharmaceuticals Third Quarter 2024 Earnings: Beats ExpectationsEton Pharmaceuticals ( NASDAQ:ETON ) Third Quarter 2024 Results Key Financial Results Revenue: US$10.3m (up 47% from 3Q... |